Aurora-kinase inhibitors as anticancer agents
By N. Keen, Stephen S. Taylor. Nature Reviews. Cancer, 2004
668 citations recorded by the source corpus.
Subfields: Cell Biology, Neurology, Oncology
View Paper: https://www.semanticscholar.org/paper/5d940fbd859f91675028f34ba5f31dc32702e5f6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Neurology
In Oncology
- Brent R. Stockwell
- Marcos Malumbres
- David M. Sabatini
- William C. Hahn
- Beth A. Weaver
- Stephen S. Taylor
- Eric S. Lander
- Scott J. Dixon
Citations in the corpus
- Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007, background): “In normal tissues, the expression of Aurora C kinase is predominantly restricted to germ cells, although the function of this enzyme remains unclea”
- A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. (2006, background): “We next examined shRNAs targeting aurora B (AURKB), a kinase that directly phosphorylates serine 10 of histone H3 during mitosis (Keen and Taylor, 2004).”
- Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival (2008, background): “These genes, such as NEK2[11,12] and CENPF[11] (both on 1q32-q41), TPX2[13,14] and STK6 (or AURKA)[15] (related to the Aurora-A activation pathway important in tumor progression[16]), TTK (linked to cell mitosis through EGFR,[17] a critical drug target for lung adenocarcinoma[18]), and BIRC5 (Surviv”
- Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development (2011, background): “Aurora kinases have recently received much attention owing to their possible involvement in tumor development and their potential therapeutic value (Keen and Taylor, 2004; Lens et al., 2010; Perez de Castro et al., 2008).”
- Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. (2008, background): “Front-runners include Eg5 kinesin inhibitors and inhibitors of mitotic kinases, such as the Auroras and Plk1 (Keen and Taylor, 2004; Bergnes et al., 2005; Strebhardt and Ullrich, 2006).”
- On the road to cancer: aneuploidy and the mitotic checkpoint (2005, background): “Additionally, aurora-kinase inhibitors diminish checkpoint signalling and cause mitoses with mis-segregation of chromosomes, failed cytokinesis and daughter cells with extra centrosome”
- Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase (2005, background): “Disruption of the Aurora B kinase-survivin-INCENP complex inhibits phosphorylation of the histone H3 protein involved in chromosome condensation and prevents cytokinesis due to loss of phosphorylated proteins on the cleavage furrow that are essential for cytokinesis (3, 10, 31, 48).”